|drug2814||Reference: Favipiravir 200 mg (Avigan) Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.
Description: AUC0-tlast of favipiravirMeasure: Primary PK End Points AUC0-tlast Time: 12 weeks
Description: Cmax of favipiravirMeasure: Primary PK End Points Cmax Time: 13 weeks
Description: AUC0-inf of favipiravirMeasure: Secondary PK End Points AUC0-inf Time: 14 weeks
Description: tmax of favipiravirMeasure: Secondary PK End Points tmax Time: 15 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports